Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA-2: Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
NCT04544293Phase 3Active, not recruiting
- Sponsor
- Savara
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Cytokines & Interferons
- Countries
- 18
01
Overview
A Phase 3 trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Started May 2021; status: active, not recruiting.
02
Drugs
molgramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT04544293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544293.